Obesity drug maker Versanis to be bought by Eli Lilly for $1.9 billion
The deal is Eli Lilly's latest attempt to capitalize on the weight loss industry gold rush, which was sparked by
Read More
Biotechnology
WHO says soda sweetener aspartame may cause cancer, but it’s safe within limits
The International Agency for Research on Cancer identified a possible link between aspartame and a type of liver cancer called
Read More
Biden administration to provide free Covid vaccines to uninsured Americans this fall through end of 2024
The HHS program aims to maintain broad access to Covid shots and treatments after the federal government shifts those products
Read More
Nvidia invests $50 million in biotech company Recursion for AI drug discovery
Nvidia is investing in Recursion, which uses AI models to identify new therapies and offers those models to its partners,
Read More
Illumina hit with record fine for closing Grail deal without EU regulatory approval
The European Commission last year blocked Illumina's $7.1 billion acquisition of Grail over concerns it would stifle innovation and consumer
Read More
White House unveils plan to eliminate threat of fentanyl laced with xylazine
The Biden administration declared the dangerous illegal drug cocktail an “emerging threat” in April for its role in fueling a
Read More
Medicare will pay for Alzheimer’s drug Leqembi. What patients and doctors should know
Patients with early Alzheimer's disease could still pay more than $5,000 in out-of-pocket costs for Leqembi even with Medicare coverage.
Read More
Sales of Alzheimer’s drug Leqembi may be slow initially but could pick up in 2024
Analysts believe the Medicare registry requirement and new guidance on Leqembi's prescription label could potentially weigh on sales in the
Read More
FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverage
Leqembi slowed cognitive decline in a clinical trial, but the treatment is expensive and carries serious risks of brain swelling
Read More